KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

BACKGROUND: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer (NSCLC). However, approximately 50% of patients do not benefit from therapy and experience rapid disease progression. PD-L1 expression is the only...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ther Adv Med Oncol
Main Authors: Cinausero, Marika, Laprovitera, Noemi, De Maglio, Giovanna, Gerratana, Lorenzo, Riefolo, Mattia, Macerelli, Marianna, Fiorentino, Michelangelo, Porcellini, Elisa, Buoro, Vanessa, Gelsomino, Francesco, Squadrilli, Anna, Fasola, Gianpiero, Negrini, Massimo, Tiseo, Marcello, Ferracin, Manuela, Ardizzoni, Andrea
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publications 2019
נושאים:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859675/
https://ncbi.nlm.nih.gov/pubmed/31798692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919885540
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים